Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$9.77
-2.2%
$10.26
$9.22
$14.63
$1.20B1.072.16 million shs1.32 million shs
Geron Corporation stock logo
GERN
Geron
$1.42
-6.0%
$1.41
$1.17
$5.06
$961.75M0.6911.15 million shs8.83 million shs
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$114.97
+0.8%
$106.86
$77.53
$129.90
$2.20B0.83117,341 shs115,184 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.27
-1.6%
$1.34
$1.19
$2.04
$1.02B1.393.86 million shs4.28 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
-2.20%-3.93%-0.31%-30.11%-14.52%
Geron Corporation stock logo
GERN
Geron
-5.96%-8.39%-2.07%-16.47%-69.46%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
+0.79%-0.03%+13.16%+4.81%+44.82%
OPKO Health, Inc. stock logo
OPK
OPKO Health
-1.55%-4.51%+0.79%-29.44%+4.10%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
4.2384 of 5 stars
3.31.00.04.72.51.71.9
Geron Corporation stock logo
GERN
Geron
3.1998 of 5 stars
3.42.00.01.31.41.70.6
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
4.4199 of 5 stars
3.50.00.04.42.63.31.9
OPKO Health, Inc. stock logo
OPK
OPKO Health
4.618 of 5 stars
3.43.00.04.42.75.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
2.50
Moderate Buy$24.00145.65% Upside
Geron Corporation stock logo
GERN
Geron
2.78
Moderate Buy$5.06256.51% Upside
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
3.00
Buy$146.1427.11% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.75
Moderate Buy$2.75116.54% Upside

Current Analyst Ratings Breakdown

Latest GERN, OPK, DVAX, and LGND Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$142.00 ➝ $145.00
5/8/2025
Geron Corporation stock logo
GERN
Geron
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeSector Outperform ➝ Sector Perform$4.00 ➝ $1.50
5/7/2025
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$33.00 ➝ $31.00
5/1/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$2.25 ➝ $2.25
4/25/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral
4/17/2025
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$12.00 ➝ $10.00
4/10/2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$143.00
4/7/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$277.25M4.23$0.15 per share63.09$4.54 per share2.15
Geron Corporation stock logo
GERN
Geron
$76.99M11.75N/AN/A$0.46 per share3.09
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$167.13M13.27$1.62 per share70.99$43.95 per share2.62
OPKO Health, Inc. stock logo
OPK
OPKO Health
$713.10M1.41$0.07 per share18.75$2.00 per share0.64
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$27.31M-$0.52N/A19.94N/A-20.39%3.59%2.20%8/5/2025 (Estimated)
Geron Corporation stock logo
GERN
Geron
-$174.57M-$0.21N/AN/AN/A-119.54%-47.86%-26.78%8/6/2025 (Estimated)
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
-$4.03M-$7.12N/A30.99N/A-73.07%-7.83%-6.92%8/5/2025 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$53.22M-$0.07N/AN/AN/A-5.66%-2.85%-1.82%8/6/2025 (Estimated)

Latest GERN, OPK, DVAX, and LGND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$1.23$1.33+$0.10-$2.21$37.84 million$45.33 million
5/7/2025Q1 2025
Geron Corporation stock logo
GERN
Geron
-$0.04-$0.03+$0.01-$0.03$49.88 million$39.60 million
5/6/2025Q1 2025
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$0.03-$0.11-$0.14-$0.77$70.01 million$68.16 million
4/30/2025Q1 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.10-$0.03-$0.10$163.13 million$149.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
N/AN/AN/AN/AN/A
Geron Corporation stock logo
GERN
Geron
N/AN/AN/AN/AN/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
0.49
11.93
10.84
Geron Corporation stock logo
GERN
Geron
0.44
7.87
6.97
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/A
5.27
5.02
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.25
2.49
2.28

Institutional Ownership

CompanyInstitutional Ownership
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
96.96%
Geron Corporation stock logo
GERN
Geron
73.71%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
91.28%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%

Insider Ownership

CompanyInsider Ownership
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
2.98%
Geron Corporation stock logo
GERN
Geron
7.42%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
7.00%
OPKO Health, Inc. stock logo
OPK
OPKO Health
49.69%
CompanyEmployeesShares OutstandingFree FloatOptionable
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
350120.08 million116.50 millionOptionable
Geron Corporation stock logo
GERN
Geron
70636.92 million589.66 millionOptionable
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
8019.29 million17.94 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
2,997793.05 million398.99 millionOptionable

Recent News About These Companies

Q1 2025 OPKO Health Inc Earnings Call
OPKO Health: Q1 Earnings Snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

Dynavax Technologies stock logo

Dynavax Technologies NASDAQ:DVAX

$9.77 -0.22 (-2.20%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$9.77 0.00 (0.00%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Geron stock logo

Geron NASDAQ:GERN

$1.42 -0.09 (-5.96%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$1.48 +0.07 (+4.58%)
As of 05:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Ligand Pharmaceuticals stock logo

Ligand Pharmaceuticals NASDAQ:LGND

$114.97 +0.90 (+0.79%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$114.98 +0.02 (+0.01%)
As of 06/23/2025 06:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.27 -0.02 (-1.55%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$1.30 +0.02 (+1.97%)
As of 06:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.